HIGHLANDS RANCH, CO., July 17, 2009-
Zipline Performance Group, a leader in consulting and training services for organizations and businesses in healthcare and other industries, today announced an agreement with the Colorado Prevention Center (CPC). Zipline will provide sales and marketing services to bring CPC's highly respected training programs to a wide audience. CPC's training is designed for clinical research coordinators, principal investigators and others in the area of clinical trials.
Leading the Zipline team will be Tom Brooksher, President and CEO, and Erik Hultman, Vice President of Sales. Both Brooksher and Hultman are veterans in designing highly effective sales, marketing and performance strategies. Mr. Brooksher has 30-plus years of successful experience in helping businesses and organizations, especially in healthcare, market and sell their training and information services. Mr. Hultman also brings an extensive background in sales and marketing for training and workforce performance services in healthcare, communications and other markets.
Based in Denver,
CPC
is a world-renowned non-profit academic research organization and community disease prevention center. Its mission is to improve health by conducting clinical research and integrating scientific findings into the practice of preventive medicine. CPC serves as a clinical trials research base and a prevention outreach facility in conjunction with the University of Colorado Denver, the Denver Health and Hospital Authority, and the National Jewish Medical and Research Center. CPC also reaches out to the community to provide preventive healthcare services and education programs, particularly in the area of cardiovascular disease, hypertension and diabetes.
With expertise in every aspect of clinical research, CPC is uniquely positioned to provide training for the conduct of clinical trials. CPC's current course, "Clinical Trials Training for Clinical Research Coordinators and Principal Investigators," has proven successful in training CPC's own workforce and partners over the past few years. The core course is available as an eight-hour, instructor-led course as well as a blended classroom-and-online program, using the innovative Confidence-Based LearningTM platform. CPC also offers an advanced level of the course available in an eight-hour, instructor-led program that covers clinical trials in depth. CPC also plans to announce more courses in the near future.
"CPC possesses academic, medical and scientific expertise in the areas of clinical research and prevention outreach services that are recognized not only in Colorado but around the world," Mr. Brooksher said. "As CPC begins to bring its training programs to a broad audience, it will lead the pack. Zipline is proud to assist CPC in this effort by offering our specialized sales and marketing services."
About Zipline Performance Group
Zipline offers an extensive platform of consulting services, custom program development and a catalog of customized learning solutions. Zipline is also a pioneer in Confidence-Based LearningTM (CBL) and one of the leading CBL developers in the world. Zipline's programs and services enable employees to accomplish more in less time; make fewer costly mistakes; increase customer satisfaction and retention; and increase revenue by growing sales, launching new products or expanding into new markets. Founded by Tom Brooksher, an expert in corporate education, distance learning and online programs, Zipline is based in Highlands Ranch, Colo. For more information, visit
www.ziplineperformance.com
.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.